The U.S. Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi). The drug, a monoclonal antibody, binds to amyloid beta in the brain. An 18-month study published in the New England Journal of Medicine found Leqembi reduced markers of amyloid in early Alzheimer’s disease and led to “moderately less decline” in cognition and function compared to placebo. However, the study added, the drug was “associated with adverse events.” Read more.